|
Dr. Martens plc (docs.l) DCF Valoración
GB | Consumer Cyclical | Apparel - Footwear & Accessories | LSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Dr. Martens plc (DOCS.L) Bundle
¡Agilice su análisis y mejore la precisión con nuestra calculadora DCF (DOCSL)! Utilizando datos reales del Dr. Martens PLC y suposiciones personalizables, esta herramienta le permite pronosticar, evaluar y valorar al Dr. Martens como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 672.2 | 773.0 | 908.3 | 1,000.3 | 877.1 | 920.0 | 965.0 | 1,012.1 | 1,061.6 | 1,113.5 |
| Revenue Growth, % | 0 | 15 | 17.5 | 10.13 | -12.32 | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 |
| EBITDA | 183.5 | 145.1 | 266.0 | 204.4 | 197.5 | 217.7 | 228.3 | 239.5 | 251.2 | 263.5 |
| EBITDA, % | 27.3 | 18.77 | 29.29 | 20.43 | 22.52 | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 |
| Depreciation | 28.9 | 33.8 | 36.7 | 54.2 | 72.3 | 48.5 | 50.9 | 53.4 | 56.0 | 58.7 |
| Depreciation, % | 4.3 | 4.37 | 4.04 | 5.42 | 8.24 | 5.27 | 5.27 | 5.27 | 5.27 | 5.27 |
| EBIT | 154.6 | 111.3 | 229.3 | 150.2 | 125.2 | 169.2 | 177.4 | 186.1 | 195.2 | 204.7 |
| EBIT, % | 23 | 14.4 | 25.24 | 15.02 | 14.27 | 18.39 | 18.39 | 18.39 | 18.39 | 18.39 |
| Total Cash | 117.2 | 113.6 | 228.0 | 157.5 | 111.1 | 157.6 | 165.3 | 173.4 | 181.8 | 190.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 55.5 | 50.7 | 75.9 | 78.8 | 54.3 | 68.5 | 71.9 | 75.4 | 79.1 | 82.9 |
| Account Receivables, % | 8.26 | 6.56 | 8.36 | 7.88 | 6.19 | 7.45 | 7.45 | 7.45 | 7.45 | 7.45 |
| Inventories | 90.0 | 101.5 | 123.0 | 257.8 | 254.6 | 174.5 | 183.1 | 192.0 | 201.4 | 211.3 |
| Inventories, % | 13.39 | 13.13 | 13.54 | 25.77 | 29.03 | 18.97 | 18.97 | 18.97 | 18.97 | 18.97 |
| Accounts Payable | 33.4 | 52.6 | 52.4 | 60.0 | 33.0 | 50.2 | 52.7 | 55.3 | 58.0 | 60.8 |
| Accounts Payable, % | 4.97 | 6.8 | 5.77 | 6 | 3.76 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 |
| Capital Expenditure | -21.9 | -17.3 | -25.0 | -51.4 | -28.4 | -30.6 | -32.1 | -33.7 | -35.3 | -37.0 |
| Capital Expenditure, % | -3.26 | -2.24 | -2.75 | -5.14 | -3.24 | -3.32 | -3.32 | -3.32 | -3.32 | -3.32 |
| Tax Rate, % | 25.59 | 25.59 | 25.59 | 25.59 | 25.59 | 25.59 | 25.59 | 25.59 | 25.59 | 25.59 |
| EBITAT | 114.5 | 55.4 | 193.9 | 121.5 | 93.2 | 123.0 | 129.0 | 135.4 | 142.0 | 148.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 9.4 | 84.4 | 158.7 | -5.8 | 137.8 | 224.0 | 138.4 | 145.2 | 152.3 | 159.7 |
| WACC, % | 5.22 | 4.52 | 5.52 | 5.42 | 5.23 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 711.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 163 | |||||||||
| Terminal Value | 5,121 | |||||||||
| Present Terminal Value | 3,978 | |||||||||
| Enterprise Value | 4,689 | |||||||||
| Net Debt | 358 | |||||||||
| Equity Value | 4,331 | |||||||||
| Diluted Shares Outstanding, MM | 986 | |||||||||
| Equity Value Per Share | 439.48 |
What You Will Receive
- Comprehensive DOCSL Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to suit your analysis.
- Automated Calculations: Dynamic calculations for intrinsic value and NPV at your fingertips.
- Scenario Testing: Explore various scenarios to assess Dr. Martens' future performance.
- User-Friendly Interface: Designed for professionals while remaining easy to navigate for newcomers.
Key Features
- 🔍 Real-Life DOCSL Financials: Pre-filled historical and projected data for Dr. Martens plc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas to determine Dr. Martens' intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Dr. Martens' valuation immediately after making adjustments.
- Scenario Analysis: Evaluate and compare different financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Dr. Martens plc (DOCSL), including historical and projected figures.
- Step 3: Modify key assumptions (highlighted in yellow) according to your analysis.
- Step 4: Observe the automatic updates for Dr. Martens' intrinsic value.
- Step 5: Utilize the results for your investment strategies or reporting needs.
Why Choose This Calculator for Dr. Martens plc (DOCSL)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Up-to-Date Financials: Dr. Martens' historical and projected financial data are included for precise analysis.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Instantly computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Intuitive step-by-step guidance makes the process simple.
Who Should Use This Product?
- Investors: Evaluate Dr. Martens’ valuation before making buy or sell decisions on stocks.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial projections.
- Startup Founders: Understand the valuation strategies of prominent public companies like Dr. Martens.
- Consultants: Create comprehensive valuation reports for clients seeking insight into Dr. Martens.
- Students and Educators: Utilize current data to practice and teach valuation methodologies effectively.
Contents of the Template
- Pre-Filled Data: Contains Dr. Martens plc's historical financial information and projections.
- Discounted Cash Flow Model: An editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated worksheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Examine Dr. Martens plc's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visualizations and tables summarizing the essential valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.